Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Peter A, MD
19 Machi 2021, 19:05:07
Didanosine na ujauzito
Kuna ripoti za ongezeko la hatari endapo la madhaifu ya kuzaliwa kwa kichanga endapo itatumika baada ya kipindi cha kwanza cha ujauzito, hata hivyo hatari ya kupata tatizo imepungua licha ya ongezeko la watumiaji. Theori zinasema kwamba endapo itatumika wakati wa kuchavushwa kwa yai, itafanya mimba isitungishwe kwa kuwa huwa sumu kijusi kwa wanyama, hii haijafanyiwa uchunguzi kwa binadamu. Hivyo endapo dawa hii iatapenekezwa kutumika, isisitishwe kwa sababu ya ujauzito.
Ushauri dhidi ya matumizi kwa mama mjamzito
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni
Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni, ina maana gani?
Kunaweza kuwa au kutokuwa na uzoefu wa matumizi ya dawa hii kwa binadamu, lakini faida ni kubwa zaidi zikitumiwa na mama kuliko madhara yanayofahamika au kutofahamika kuwa yanaweza kutokea kwa kijusi-kichanganya tumboni. Kwa mama dawa zinazidi madhara yanayofahammika. Taarifa za uzazi kwa wanyama hazina mahusiano.
Ushauri wa matumizi kwa mama anayenyonyesha
Haipatani na unyonyeshaji
Haipatani na unyonyeshaji, ina maana gani?
Kunawezekana kuwa hakuna taarifa za uzoefu wa matumizi ya dawa hii kwa mama anayenyonyesha. Hata hivyo mkusanyiko wa taarifa zinaonyesha kuwa dawa huweza kuwa sumu kali kwa kichanga, au haishauriwi kunyonyesha endapo dawa itahitajika kutumika kwa mama mwenye anayehitajika kutumia dawa hii. Mama anatakiwa asinyonyeshe anapotumia dawa hii au akiwa na ugonjwa unaotakiwa kutumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023, 17:21:36
rejea za mada hii
1. Product information. Videx. Bristol-Myers Squibb, 2001.
2. Sieh E, et al. The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study. AIDS Res Hum Retroviruses 1992;8:639–49.
3. Klug S, et al. In vitro and in vivo studies on the prenatal toxicity of five virustatic nucleoside analogues in comparison to aciclovir. Arch Toxicol 1991;65:283–91.
4. Toltzis P, et al. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100–2.
5. Esterman AL, et al. The effect of zidovudine and 2′3′-dideoxyinosine on human trophoblast in culture. Pharmacol Toxicol 1995;76:89–92.
6. Plessinger MA, Miller RK. Effects of zidovudine (AZT) and dideoxyinosine (ddI) on human trophoblast cells. Reprod Toxicol 1999;13:537–46.
7. Pereira CM, Nosbisch C, Winter HR, Baughman WL, Unadkat JD. Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. Antimicrob Agents Chemother 1994;38:781–6.
8. Sandberg JA, et al. Placental transfer and fetal disposition of 2′3′-dideoxycytidine and 2′3′-dideoxyinosine in the rhesus monkey. Drug Metab Dispos 1995;23:881–4.
9. Bawdon RE, Sobhi S, Dax J. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol 1992;167:1570–4.
10. Dancis J, et al. Transfer and metabolism of dideoxyinosine by the perfused human placenta. J Acquir Immune Defic Syndr 1993;6:2–6.
11. Henderson GI, et al. Transfer of dideoxyinosine across the human isolated placenta. Br J Clin Pharmacol 1994;38:237–42.
12. Pons JC, et al. Fetoplacental passage of 2′,3′-dideoxyinosine. Lancet 1991;337:732.
13. Dalton JT, Au JL-S. 2′3′-Dideoxyinosine is not metabolized in human placenta. Drug Metab Dispos 1993;21:544–6.
14. Tuntland T, et al. In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus. Am J Obstet Gynecol 1999;180:198–206.